Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/geron-stock-falls-22-after-myelofibrosis-trial-halt.webp

Geron Falls 16% After Myelofibrosis Trial Halt

TIM BOHEN•UPDATED OCT. 28, 2026, 9:29 PM ET
Reviewed by Ben Sturgilland Fact-checked by Jack Kellogg

Geron fell 16% after stopping its myelofibrosis trial because an independent committee saw little chance it would meet its survival goal.

GERN Candlestick Chart

Get Free Alerts

Why Geron Stock Is Down Today

Geron Corporation (NASDAQ: GERN) is down 16% at $0.97 in after-hours trading after announcing it will stop its Imetelstat trial in the blood cancer myelofibrosis. An independent committee found it unlikely to show patients lived longer, ending a possible use for the drug beyond its approved blood-disorder treatment. Trading reached about 83 million shares, about eleven times the normal pace.

What Geron Corporation Does

Geron sells Rytelo, its approved form of Imetelstat for certain blood disorders. Earlier employee grants gave new hires options to buy shares at $1.17, the price they would pay to exercise them.

Geron Imetelstat Myelofibrosis Trial

The study was in Phase 3, the final large test before drug regulators decide, for myelofibrosis, which disrupts blood-cell production. Patients’ disease had returned or persisted after medicines that block signals involved in blood-cell production. Geron reported no new safety concerns from the study.

Quick Financial Overview

Geron has real sales but remains unprofitable, with about fifty-seven months of funding at its latest spending rate. It held $300.8M in cash, cash equivalents, and short-term investments as of June 30, 2026, including cash and holdings readily turned into money. Its $623.3M stock-market value makes it a small-cap, smaller than major drugmakers.

Geron Revenue and Earnings

In its latest quarter, Geron reported $57.5M in sales and a net loss of $16.7M. The loss shows those sales have not yet made the company profitable.

Get Free Alerts

Geron Stock Extends Its Longer Decline

Geron traded around $1.25 a month ago and is down 36% over six months and down 24% over a year. That points to a longer decline, with today’s news adding pressure rather than ending a recent climb. This was unusual even within that decline: the last daily move this large was fifty-nine sessions ago.

Trading Perspective

GERN opened below its previous closing price and now trades below around $1.00, the lower edge of that opening drop. The annual high at around $2.00 is a past price above the current price, not a prediction of where shares will go.

Rytelo Approval for Lower-Risk Blood Disorders

Rytelo is approved for certain patients with lower-risk myelodysplastic syndromes, blood disorders in which bone marrow makes abnormal blood cells. That approval covers patients in the United States and European Union. Wedbush, an investment firm, cited growth in customers ordering the drug as a reason for further sales gains.

Get Free Alerts

Conclusion

Third-quarter results arrive before the market opens on November 4, 2026; stronger sales would support Rytelo’s outlook, while weakness could hurt it. The company plans to share its trial analysis later, but no replacement myelofibrosis study or regulatory step is announced. Its reported cash covers the wait at the latest spending rate.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders